2-[4-(4-tert-butylphenyl)sulfonylpiperazin-1-yl]-1,3-benzoxazole | 695221-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-[4-(4-tert-butylphenyl)sulfonylpiperazin-1-yl]-1,3-benzoxazole
• 英文别名: Benzooxazole, 2-[4-(4-tert-butylbenzenesulfonyl)piperazin-1-yl]-
• CAS: 695221-93-3
• 化学式: C₂₁H₂₅N₃O₃S
• mdl: MFCD04060375
• 分子量: 399.514
• InChiKey: NIRRBOUULIAGFK-UHFFFAOYSA-N

物化性质

• 沸点：
  546.6±60.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对叔丁基苯磺酰氯 、 2-哌嗪基-1,3-苯并恶唑 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以77%的产率得到2-[4-(4-tert-butylphenyl)sulfonylpiperazin-1-yl]-1,3-benzoxazole
  参考文献：
  名称：

  Synthesis and biological analysis of benzazol-2-yl piperazine sulfonamides as 11β-hydroxysteroid dehydrogenase 1 inhibitors

  摘要：

  In the last decade the inhibition of the enzyme 11 beta-hydroxysteroid dehydrogenase 1 (11 beta-HSD1) emerged as a promising new strategy to treat diabetes and several metabolic syndrome phenotypes. Using a molecular modeling approach and classical bioisosteric studies, we discovered a new class of 11 beta-HSD1 inhibitors bearing an arylsulfonylpiperazine scaffold. Optimization of the initial lead resulted in compound 11 that selectively inhibits 11 beta-HSD1 (IC50 = 0.7 mu M). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.047

文献信息

• Synthesis and biological analysis of benzazol-2-yl piperazine sulfonamides as 11β-hydroxysteroid dehydrogenase 1 inhibitors
  作者：Sandra Hofer、Denise V. Kratschmar、Brigitte Schernthanner、Anna Vuorinen、Daniela Schuster、Alex Odermatt、Johnny Easmon

  DOI：10.1016/j.bmcl.2013.07.047

  日期：2013.10

  In the last decade the inhibition of the enzyme 11 beta-hydroxysteroid dehydrogenase 1 (11 beta-HSD1) emerged as a promising new strategy to treat diabetes and several metabolic syndrome phenotypes. Using a molecular modeling approach and classical bioisosteric studies, we discovered a new class of 11 beta-HSD1 inhibitors bearing an arylsulfonylpiperazine scaffold. Optimization of the initial lead resulted in compound 11 that selectively inhibits 11 beta-HSD1 (IC50 = 0.7 mu M). (C) 2013 Elsevier Ltd. All rights reserved.